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Abstract
Background: Pseudomonas aeruginosa is an opportunistic pathogen that is the major cause of morbidity and
mortality in patients with cystic fibrosis (CF). While most CF patients are thought to acquire P. aeruginosa from the
environment, person-person transmissible strains have been identified in CF clinics worldwide. The molecular basis
for transmissibility and colonization of the CF lung remains poorly understood.
Results: A dual proteomics approach consisting of gel-based and gel-free comparisons were undertaken to analyse
protein profiles in a transmissible, early (acute) isolate of the Australian epidemic strain 1 (AES-1R), the virulent
burns/wound isolate PA14, and the poorly virulent, laboratory-associated strain PAO1. Over 1700 P. aeruginosa
proteins were confidently identified. AES-1R protein profiles revealed elevated abundance of proteins associated
with virulence and siderophore biosynthesis and acquisition, antibiotic resistance and lipopolysaccharide and fatty
acid biosynthesis. The most abundant protein in AES-1R was confirmed as a previously hypothetical protein with
sequence similarity to carbohydrate-binding proteins and database search revealed this gene is only found in the
CF-associated strain PA2192. The link with CF infection may suggest that transmissible strains have acquired an
ability to rapidly interact with host mucosal glycoproteins.
Conclusions: Our data suggest that AES-1R expresses higher levels of proteins, such as those involved in antibiotic
resistance, iron acquisition and virulence that may provide a competitive advantage during early infection in the
CF lung. Identification of novel proteins associated with transmissibility and acute infection may aid in deciphering
new strategies for intervention to limit P. aeruginosa infections in CF patients.
Background
Pseudomonas aeruginosa is a Gram negative opportunistic
pathogen with an extraordinary capacity to survive in, and
adapt to, a wide range of environmental niches. Genome
size (approximately 5500 genes [1]) and plasticity enable
the expression of an arsenal of surface-associated and
secreted virulence factors [2], which contribute to nosoco-
mially-acquired P. aeruginosa infections, particularly those
involving burns and wounds, as well as meningitis, endo-
carditis and microbial keratitis. P. aeruginosa is also the
major determinant of morbidity and mortality in patients
suffering from the autosomal recessive disorder cystic
fibrosis (CF) [3]. CF patients display electrolyte transport
imbalance and dysfunction across many organ systems. In
the lungs, this is characterized by the production of a
thickened dehydrated mucus layer, which provides an
environment suitable for colonization by pathogens [4].
Although many species are able to colonize the CF lung,
including Staphylococcus aureus and Haemophilus influen-
zae, P. aeruginosa will eventually dominate in the majority
of patients. Initial P. aeruginosa infections may be cleared
by antibiotics, however biofilm formation allows persis-
tence that is associated with antibiotic resistance and
chronic infection [5]. Strains of P. aeruginosa associated
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with CF infections are likely to contain and/or express
genes that confer functional traits allowing initial coloniza-
tion of the CF lung mucosa as well as the ability to out-
compete other pathogens.
Contrary to the dogma that CF patients acquire unique
P. aeruginosa from an environmental source [6], it has
now become evident that person-to-person transmissible
strains may circulate within CF clinics [7-11]. Such strains
have been found in the United Kingdom and Europe
(Manchester epidemic strain [MA], Liverpool epidemic
strain [LES] [10,11] and Clone C [12]), as well as Canada
[13] and Australia (Australian epidemic strain 1 [AES-1]
[7]). Increasing evidence suggests that transmission
between patients occurs via a cough-associated aerosol
route [14,15]. The majority of epidemic strains display evi-
dence of increased virulence in CF patients [16] and trans-
mission to patients with non-CF bronchiectasis, or even
otherwise healthy relatives, has been detected [17]. Little is
known however, about the mechanisms underlying trans-
missibility and pathogenesis of epidemic P. aeruginosa.
Isolates from initial infection tend to be non-mucoid and
motile, but over time the organism undergoes genotypic
and phenotypic changes that promote persistence, includ-
ing conversion to mucoidy, loss of motility and reduced
type III secretion consistent with biofilm formation [18].
Whole genome sequencing of two clonally related isolates
collected from a CF patient 7.5 years apart [18] (early
infection and chronic infection) showed loss of function in
virulence genes required for O-antigen biosynthesis, type
III secretion, twitching motility, exotoxin A regulation,
multi-drug efflux, phenazine biosynthesis, quorum sensing
(QS) and iron acquisition.
Horizontal gene transfer and recombination in gene
islands, large chromosomal inversions and gene loss are
important in P. aeruginosa evolution [19,20], and phenoty-
pic traits may also be acquired from infecting bacterioph-
age. P. aeruginosa Clone C carries a plasmid and genomic
islands with sequences substantially different from the
P. aeruginosa reference clone PAO1 that may confer
enhanced colonization and survival [21]. Adaptation by
P. aeruginosa to the CF lung is also accelerated by the
host immune response and nutrient limitation, including
oxidative stress and iron availability, as well as antibiotic
challenge. While the Clone C, AES-1, LES and MA epi-
demic strains do not appear closely related to each other
[22], a shared phenotype is the expression of biofilm-asso-
ciated genes. Analysis of CF isolates show increased
expression of QS, bacteriophage and other genes that are
indicative of iron limited, stationary phase, and oxygen-
limited growth [23,24] and many of these correlate with in
vivo transcriptome analysis [25]. Despite the accumulation
of evidence regarding gene expression during infection,
the molecular basis for transmissibility is almost comple-
tely unknown.
In this study, we employed a complementary proteomic
approach involving two-dimensional gel electrophoresis (2-
DE) and two-dimensional liquid chromatography coupled
to tandem mass spectrometry (2-DLC-MS/MS) with isoba-
ric tags for relative and absolute quantitation (iTRAQ) to
determine protein abundance differences between the
reference strain P. aeruginosa PAO1, the virulent burn/
wound isolate UCBPP-PA14 (PA14) and the early, trans-
missible CF-associated P. aeruginosa AES-1R. We identi-
fied over 1700 proteins of which 183 were present at
statistically significant altered abundance between strains.
This study identified 3 previously hypothetical proteins
only expressed in strain AES-1R, of which AES_7139 was
the most abundant protein detected on 2-DE gels. Other
proteins present at elevated abundance in AES-1R com-
pared to PA14 and PAO1 included several secreted and
iron acquisition proteins, such as those associated with
pyochelin synthesis and binding. AES-1R displayed an
absence or decreased abundance of a number of porins
including OprE, OprG and OprD, but elevated abundance
of the multi-drug efflux protein MexX, part of the MexXY-
OprM tripartite efflux pump. AES-1R also displayed differ-
ential abundance of proteins involved in lipopolysaccharide
and fatty acid biosynthesis. These data suggest that AES-
1R expresses specific proteins and regulates the abundance
of proteins shared with other P. aeruginosa strains to influ-
ence transmissibility and colonization of the CF lung.
Methods
Bacterial strains and growth conditions
P. aeruginosa PAO1 is a laboratory reference strain origin-
ally isolated from an infected burn/wound of a patient in
Melbourne, Australia (American Type Culture Collection
ATCC 15692), strain PA14 (UBPPC-PA14) was obtained
from Dr. Laurence Rahme, Harvard Medical School, Cam-
bridge, MA [26] and AES-1R was obtained from Prof.
David Armstrong, Monash Medical Centre, Australia [7].
Strains were cultured in six replicates of 50 mL of salt
modified Luria-Bertani broth (5 g/L NaCl) and grown to
stationary phase (OD600 nm ~ 1.0) with incubation at 37°C
and shaking at 250 × rpm (Additional file 1). Cultures
were harvested, washed three times with phosphate-
buffered saline and cells collected by centrifugation at
6,000 × g for 10 mins at 4°C. The resulting bacterial cell
pellets were frozen, lyophilized and stored at -80°C.
Phenotypic assays
Phenotypic assays on P. aeruginosa AES-1R, PAO1 and
PA14 were conducted using standard methodologies.
Briefly, mucoidy (from - [non-mucoid] to +++ [highly
mucoid]) and colony size were assessed by growth on
Columbia horse blood agar (Oxoid, Basingstoke UK)
and Mueller-Hinton (Oxoid) agar. Pyocyanin production
was scored against colour standards from overnight LB
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broth cultures grown at 37°C. For pyoverdine produc-
tion, 5 μL of overnight LB culture was spotted on to a
King’s B agar plate, allowed to dry and incubated for
24 h at 37°C, and assayed based on the zone of pigmen-
tation around the colony. Rhamnolipid, phospholipase C
(PLC), haemolysin, total protease and elastase assays
were conducted using 5 μL each of overnight LB culture
spotted onto agar as follows: i) rhamnolipid, M9 agar; ii)
PLC, egg yolk agar (Oxoid); iii) haemolysin, Columbia
horse blood agar; iv) total protease, 10 mL skim milk
agar; and v) elastase, 10 mL elastin agar. Each assay was
incubated for 24-48 h at 37°C and the diameters of
clearing zones measured. Each assay was conducted in
at least triplicate. Biofilm forming properties were mea-
sured using a 1:100 dilution of an overnight LB broth
culture in fresh LB medium. 100 μL was added to each
well of a flat bottom MicroTest tissue culture plate (BD,
Franklin Lakes NJ) and incubated in a moist environ-
ment at 37°C for 24 h. Wells were stained with 200 μL
0.5% crystal violet for 3 h before dissolving in 200 μL
20% (v/v) acetone. Absorbance was then read at
620 nm. Swimming motility was assayed by spotting a
single colony onto a 0.3% LB agar plate and incubating
for 24 h at 37°C. Twitching motility was assayed by
stabbing a colony into the bottom of a 10 mL 1% LB
agar plate and incubating for 24 h at 37°C. In both cases
motility was measured by the diameter of the resulting
growth zones.
Preparation of protein extracts for 2-DE
Proteins were extracted from 10 mg of lyophilized bacter-
ial cell pellets in 1 mL 40 mM Tris (pH 7.8) by tip-probe
sonication (Branson, Danbury CT) using 4 cycles of 30 s
with resting on ice between cycles. Nucleic acids were
removed by incubation with 150 U endonuclease (Sigma,
St. Louis MO) for 20 mins at room temperature. Lysates
were then centrifuged at 12,000 × g for 15 mins at 15°C to
remove insoluble material. Resulting supernatants were
methanol precipitated overnight at -80°C and the proteins
collected by centrifugation at 12,000 × g for 30 mins at
4°C. Proteins were then resuspended in 1 mL of 2-DE buf-
fer (5 M urea, 2 M thiourea, 2% [w/v] CHAPS, 2% [w/v]
sulfobetaine 3-10, 40 mM Tris, 0.2% [v/v] carrier ampho-
lytes, 0.002% [v/v] bromophenol blue and 2 mM tributyl-
phosphine [TBP]).
Separation of proteins by 2-DE
Proteins (250 μg) were loaded onto 17 cm pH 4-7 immo-
bilized pH gradient (IPG) strips (Bio-Rad, Hercules CA)
by overnight passive rehydration. Isoelectric focussing was
carried out using a Bio-Rad IEF Cell for a total of 80 kVh.
Proteins in IPG strips were detergent exchanged, reduced
and alkylated in 6 M urea, 2% (w/v) SDS, 20% (v/v) gly-
cerol, 5 mM TBP, 2.5% (v/v) acrylamide monomer and
375 mM Tris-HCl (pH 8.8) for 20 mins. Strips were then
embedded on an 8-18%T gradient SDS-PAGE gel using
0.5% (w/v) agarose in 25 mM Tris, 192 mM glycine, 0.1%
(w/v) SDS. Proteins were separated in a Dodeca Cell (Bio-
Rad) at 16°C at 10 V constant voltage for 30 mins followed
by 100 V for 16 h. Gels were fixed in 40% (v/v) methanol,
10% (v/v) acetic acid for 1 h and then stained overnight in
Sypro Ruby (Bio-Rad). Gels were destained in 10% (v/v)
methanol, 7% (v/v) acetic acid for 1 h and imaged using a
Molecular Imager Fx (Bio-Rad). Gels were ‘double-stained’
for a minimum of 24 h in Colloidal Coomassie Blue G-250
(0.1% (w/v) G-250 in 17% (w/v) ammonium sulphate, 34%
(v/v) methanol and 3% (v/v) ortho-phosphoric acid). Gels
were destained in 1% (v/v) acetic acid for a minimum of
1 h.
Changes in protein abundance were compared for 2-DE
gels generated from each strain using the program PD-
Quest (Bio-Rad). Since the x,y-coordinates of spots on 2-
DE gels from different bacterial isolates are not always
identical due to minor amino acid sequence variations
that lead to altered electrophoretic migration, we under-
took a protein mapping exercise to identify like proteins
across isolates, as well as image-based comparisons. Spots
between isolates corresponding to the same protein identi-
fications were detected using PD-Quest and the relative
spot intensities (in ppm) calculated. Statistical analyses
were performed on six replicate 2-DE gels corresponding
to two gels from each of three separate biological prepara-
tions. The cut-off for significance was an n-fold change in
mean spot abundance of less than 0.67 or greater than 1.5
with a p-value less than 0.05, or spots with a ratio less
than 0.77 or greater than 1.3 with a p-value less than 0.01.
Mean spot density values were calculated for each spot
across replicate gels and standard error of the mean
(SEM) determined. Spots absent from a given strain were
denoted as not detected (-), while those only present in
that strain were labeled (+). If the SEM was greater than
15% of the calculated mean, the spot was not investigated
further. Students’ t-test was performed on the normalized
spot intensities, with significance levels set at 0.05.
Protein identification by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF MS)
peptide mass mapping
Spots were destained in a 60:40 solution of 40 mM
NH4HCO3 (pH 7.8)/100% acetonitrile (MeCN) for 1 h.
Gel pieces were vacuum-dried for 1 h and rehydrated in
8 μL of 12 ng/μL of trypsin at 4°C for 1 h. Excess trypsin
was removed and gel pieces re-suspended in 25 μL of
40 mM NH4HCO3 and incubated overnight at 37°C.
Peptides were concentrated and desalted using C18 Zip-
Tips (Millipore, Bedford MA) and eluted in matrix (a-
cyano-4-hydroxy cinnamic acid (Sigma), 8 mg/mL in 70%
[v/v] MeCN/1% [v/v] formic acid [FA]) directly onto a
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target plate. Peptide mass maps were generated by matrix-
assisted laser desorption/ionisation time-of-flight mass
spectrometry (MALDI-TOF MS) using a QSTAR Elite
mass spectrometer (Applied Biosystems, Foster City CA)
equipped with o-MALDI source. Spectra were examined
in Analyst v2.0 (Applied Biosystems) and mass calibration
performed prior to data acquisition using external calibra-
tion with the Sequazyme™ peptide mass standard kit
(Applied Biosystems). Peak lists from each spot were gen-
erated by manual interrogation of the spectra. Data from
peptide mass maps were used to perform searches of a
composite P. aeruginosa database composed of translated
genome sequences from PAO1 (Pseudomonas Genome
Database v2, 2009-11-23), PA14 (Pseudomonas Genome
Database v2, 2009-10-14) and AES-1R (unpublished gen-
ome sequence data) via an in-house MASCOT server
(Matrix Science; v2.2; [complete database 18.694 protein
entries]). Identification parameters included peptide mass
accuracy within 0.08 Da, one possible missed tryptic clea-
vage per peptide and with the methionine sulfoxide and
cysteine-acrylamide modifications checked. Identifications
were based on MASCOT score, observed pI and mass
(kDa), number of matching peptide masses and total per-
centage of the amino acid sequence that those peptides
covered.
Where insufficient data were obtained for a confident
identification using peptide mass mapping, reversed
phase liquid chromatography coupled to tandem MS
(RPLC-MS/MS) with de novo sequencing of peptides
was performed. Protein spots were digested as above
and the peptides concentrated and desalted using a col-
umn packed with Poros R2 resin [27]. Columns were
primed with 97% MeCN, acidified with 0.1% trifluoroa-
cetic acid (TFA), and the digested peptides loaded.
Bound peptides were washed twice with 0.1% TFA and
eluted with 70% MeCN/0.1% TFA. Eluted peptides
were dried by vacuum centrifugation and resuspended
in 0.1% FA. Peptides were separated using an auto-
mated Agilent 1100 nanoflow LC system coupled to an
Applied Biosystems Q-STAR Elite mass spectrometer
for MS/MS sequencing. Peptides were eluted over 30
mins using a gradient of 5-60% buffer B (0.1% [v/v] FA,
100% MeCN) at a nanoflow rate of 600 nL/min. MS
survey scans were performed over the m/z range of
400-1800 (three scans), followed by three data-depen-
dent MS/MS scans. Data were analyzed using Analyst
and the resulting MS/MS data were searched against
the aforementioned P. aeruginosa database using MAS-
COT with the following parameters; allow 1 missed
cleavage, precursor mass tolerance 0.2 Da, fragment
ion mass tolerance 0.6 Da, with methionine sulfoxide,
cysteine-acrylamide, and carbamidomethylation vari-
able modifications selected.
Quantitative proteomics using iTRAQ and two-
dimensional liquid chromatography/tandem mass
spectrometry (2-DLC-MS/MS)
Proteins were extracted from 10 mg of lyophilized bacteria
in 1 mL 0.1% (w/v) SDS by tip-probe sonication as
described above. Proteins were precipitated from the cell
lysate by methanol/chloroform as per [28] and collected
by centrifugation at 9000 × g for 2 mins. The resulting
supernatant was removed and the pellet washed 3 times
with 1 mL ice-cold methanol. Protein pellets were resus-
pended in 0.5 M triethylammonium bicarbonate (TEAB;
pH 7.8)/0.1% (w/v) SDS. Proteins from each of the P. aeru-
ginosa isolates were then labelled with isobaric tags for
relative and absolute quantitation (iTRAQ; Applied Bio-
systems). 50 μg of each protein sample was reduced with
10 mM Tris 2-carboxyethyl phosphine (TCEP) at 60°C for
1 h, then alkylated with 9 mM methyl (methylthio)methyl
sulfoxide (MMTS) at room temperature for 10 mins,
followed by digestion with trypsin (6 μg/50 μg protein) at
37°C overnight. Digested protein samples were dried by
vacuum centrifugation and resuspended in 0.5 M TEAB.
Duplicate 4-plex iTRAQ experiments were conducted
with the following labelling of samples: P. aeruginosa
PAO1 (label 114), P. aeruginosa PA14 (115), P. aeruginosa
AES-1R (116), and a biological replicate of P. aeruginosa
PAO1 (117) in the first experiment and AES-1R in the
second. Samples were labelled according to the manufac-
turer’s instructions. Briefly, iTRAQ labels were resus-
pended in 70 μL ethanol and added to the appropriate
protein sample. Labelling was conducted at room tem-
perature for 2 h, and the reaction quenched with 100 μL
ultra-pure water. Labelling efficiency was tested by pooling
2 μL aliquots of all labelled samples, desalting peptides as
described above, and then acquiring MALDI TOF-TOF
MS/MS data on a 4700 mass spectrometer (Applied Bio-
systems). All samples showed a 1:1:1:1 labelling efficiency.
Labelled samples were pooled, dried to near completion
by vacuum centrifugation and resuspended in 5 mM phos-
phate buffer/25% (v/v) MeCN (pH 2.7).
Labelled peptides were then separated by two-dimen-
sional liquid chromatography (2-DLC) and identified by
MS/MS. Peptides were fractionated by strong cation
exchange (SCX) chromatography using an Agilent 1100
HPLC with a PolyLC (Columbia MD) polysulfoethyl A
200 mm × 2.1 mm 5 μm 200 Å column. Peptides were
loaded and washed in buffer A (5 mM phosphate buffer/
25% [v/v] MeCN, pH 2.7). Fractions were then collected at
2-4 min intervals during an 80 mins gradient from 10% to
45% buffer B (5 mM phosphate buffer/350 mM KCL/25%
[v/v] MeCN, pH 2.7) over 70 mins and then, following a
rapid increase, to 100% buffer B for 10 mins at a flow rate
of 300 μL/min. SCX fractions were vacuum concentrated
and resuspended in 100 μL of 0.1% (v/v) TFA/2% (v/v)
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MeCN. A Tempo nanoLC (Eksigent, Dublin CA) and Q-
Star Elite mass spectrometer (Applied Biosystems) were
used for nanoLC electrospray ionisation MS-MS. A 40 μL
aliquot of the resuspended sample was loaded on a reverse
phase Captrap (Michrom Bioresources, Auburn CA) col-
umn and desalted at 10 μL per min for 13 mins. After
desalting, the trap was switched on-line and peptides sepa-
rated by reversed phase chromatography using a 150 μm ×
10 cm C18 3 μm 300 Å ProteCol column (SGE Analytical
Science, Ringwood Australia). After washing with buffer A
(0.1% [v/v] FA), buffer B (90% [v/v] MeCN/0.1% [v/v] FA)
concentration was increased from 5% to 90% in 120 mins
using three linear gradient steps. The reverse phase
nanoLC eluent was subjected to positive ion nanoflow
electrospray ionisation MS/MS analysis in an information
dependant acquisition mode (IDA). A TOF MS survey
scan was acquired (m/z 380-1600, 0.5 s scan time), with
the three most intense multiply charged ions (counts > 50)
in the survey scan subjected to MS/MS. MS/MS spectra
were accumulated in the mass range m/z 100-1600 with a
modified Enhance All Q2 transition setting favouring low
mass ions so that the reporter iTRAQ tag ions (114, 115,
116 and 117 Da) were enhanced for relative quantitation.
Protein identification was performed by combining all
the data from each SCX fraction following acquisition of
the MS/MS raw files. All data were processed using Pro-
teinPilot (Applied Biosystems, version 2.01) using the
Paragon search algorithm. The software correction factors
provided in the iTRAQ manufacturer’s instructions were
entered in the iTRAQ Isotope Correction Factors table.
Data were searched using the combined P. aeruginosa
database described above and a randomized version of the
database to calculate false discovery rate (FDR). Search
parameters included trypsin as the proteolytic enzyme, up
to two possible missed cleavages and MMTS as the
selected alkylating agent. Data were filtered to a 1% FDR
and the minimum number of unique peptides was set to
1. For all proteins identified on the basis of a single confi-
dent peptide identification, the MS/MS spectra were
manually verified according to [29]. Spectra with missing
iTRAQ labels were omitted from quantitative analysis,
unless the corresponding gene was not present in one or
more P. aeruginosa strains under study. iTRAQ ratios less
than 0.67 or greater than 1.5 with a p-value less than 0.05,
or proteins with a ratio less than 0.77 or greater than 1.3
with a p-value less than 0.01, and with consistent results
across replicate iTRAQ experiments were deemed signifi-
cantly differentially abundant.
Results
Phenotypic analysis of P. aeruginosa AES-1R compared to
PAO1 and PA14
P. aeruginosa AES-1R was isolated from a child aged 14
months at the same time as the deaths of 5 CF infants
infected with AES-1 [7]. The genome sequence has
recently been completed [30]. We undertook phenotypic
assays to determine the general virulence properties of
AES-1R compared to PAO1 and PA14 (Table 1). AES-
1R displayed small colonies after 48 h and may therefore
qualify as a small colony variant. AES-1R was also non-
mucoid and displayed little biofilm formation capability,
which are traits consistent with acute CF isolates. For
virulence factor assays, AES-1R produced high levels of
pyocyanin, and more elastase, total protease and PLC
than PAO1 (but less than PA14). Rhamnolipid and
hemolysin appeared to be consistent between PAO1 and
AES-1R. AES-1R was also comparable in both swim-
ming and twitching motility with both PAO1 and PA14.
Comparative gel-based proteomics of P. aeruginosa PAO1,
PA14 and AES-1R
Soluble proteins were extracted from stationary phase LB
broth cultures of P. aeruginosa strains PAO1, PA14 and
AES-1R, and separated by 2-DE. All visible protein spots
were excised and identified by MALDI-TOF MS peptide
mass mapping following in-gel trypsin digestion. Since
many potentially ‘unique’ protein spots detected by image
analysis may be accounted for by minor amino acid
sequence differences between isolates that result in spot
shifts (change in 2-DE x,y-coordinates), we performed sta-
tistical analysis only on spots with the same identity, or
those that were identified in one isolate alone. A total of
154 unique proteins were identified from 563 spots (data
not shown), with 54 spots (representing 43 unique pro-
teins) displaying a significant difference in abundance
between AES-1R and either, or both of, PAO1 and PA14
(Figure 1 and Additional file 2).
Analysis of the spots that changed in abundance showed
that 27 were altered identically (statistically significant
change in abundance and either increased or reduced in
Table 1 Phenotypic characterization of P.aeruginosa AES-
1R compared to PAO1 and PA14
Phenotypic Characteristic AES-1R PAO1 PA14
Mucoidy (+/-) - - -
Pyocyanin (+/-) +++ + +++
Pyoverdine (+/-) + + +
Biofilm (Abs 620 nm) 0.06 ± 0.03 0.11 ± 0.04 0.27 ± 0.06
Elastase (dmm) 17.67 ± 3.12 12.00 ± 0.67 21.33 ± 2.01
Rhamnolipid (dmm) 9.0 ± 0.50 10.0 ± 0.7 11.0 ± 1.0
Phospholipase C (dmm) 17.33 ± 0.87 16.25 ± 1.02 23.33 ± 1.67
Hemolysin (dmm) 7.0 ± 0.4 7.0 ± 0.8 11.0 ± 0.6
Total Protease (dmm) 17.0 ± 1.3 14.0 ± 1.4 19.0 ± 2.3
Swimming Motility (dmm) 37.50 ± 4.79 29.25 ± 5.87 35.00 ± 1.06
Twitching Motility (dmm) 12.5 ± 3.8 17.3 ± 1.1 NP
dmm; diameter in mm; +/-, characteristics measured on a relative scale of (-)
no evidence of that phenotype; (+) low, (++) intermediate and (+++) high. NP,
not performed
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abundance) in AES-1R compared to both PAO1 and
PA14. A further 16 spots were altered in abundance in
AES-1R compared to PA14, but not PAO1, while 9 spots
were altered in AES-1R compared to PAO1, but not
PA14. A single spot (spot 31) was statistically significantly
more abundant in AES-1R compared to PA14, but less
abundant in AES-1R compared to PAO1, while an addi-
tional spot (spot 20d) was present at lower abundance in
AES-1R than PA14, but not detected in PAO1. The differ-
entially abundant proteins were functionally clustered into
4 major groups: i) membrane-associated proteins; ii) heat
shock proteins/chaperones; iii) oxidative stress proteins;
and iv) previously hypothetical proteins. Fourteen proteins
were classified as ‘membrane-associated’, of which 8
(Opr86, PA4595, OprQ, flagellin type B, OprF, PA5217,
OmpA and PasP) were elevated in abundance in AES-1R,
and 6 (FptA, OmpH, PA2291, OprE, OprD and OprG)
were present at lower abundance in AES-1R, compared to
either or both, of PAO1 and PA14. All 4 heat shock pro-
teins (HtpG, DnaK, GroEL and PA4352) were elevated in
AES-1R compared to both PAO1 and PA14. Five proteins
involved in oxidative stress resistance (PA3529, AhpC,
PA4880, PA2331 and KatA) were altered in AES-1R, with
all except KatA present at increased abundance. Addi-
tional smaller functional clusters included the 3 enzymes
of the arginine deiminase pathway (ArcABC) and the ATP
synthase alpha and beta subunits.
We identified 2 proteins that were expressed from
genes only encoded in the AES-1R genome (spots 26 and
43), and a further protein that was not contained within
the PAO1 genome (spot 37). Previously hypothetical pro-
tein AES_7139 (spots 43 a-e; Figure 1) was the most
abundant protein identified on the 2-DE gels of AES-1R
and is present in multiple mass and pI variants. Variants
exist at two masses, approximately 28 kDa and 16 kDa,
with three pI variants at the higher mass (pI 5.2, 5.6, and
6.0), and two pI variants at the lower mass (pI 5.2 and
6.0). We subjected these spots to both MALDI-TOF MS
peptide mass mapping and to LC-MS/MS for sequence
characterization. We identified 9 peptide sequences that
generated 90.8% sequence coverage for the predicted
AES-1R gene (Figure 2). All variants generated near iden-
tical MALDI-MS spectra, suggesting the unusual migra-
tory pattern on 2-DE gels are due to folding artifacts or
poorly reduced disulfide bonds [31-33]. The AES_7139
translated gene sequence is predicted to encode a protein
of 16.7 kDa and with a pI of 5.3, suggesting the higher
mass variants may be homodimers or artifacts of the gel
process. The sequence contains a single cysteine residue
through which a disulfide could be formed, however
under the reducing conditions used to conduct 2-DE, it is
more likely that a gel artifact results in the spot pattern.
One of the peptides sequenced by MS/MS displayed a
non-tryptic N-terminus 8-GTYLFQYAQDKDYVLGVS-
DEQSGAK-32 (2782.4093 m/z) cleaved between Met-7
and Gly-8 that suggests either N-terminal processing, or
that Met-7 is the true N-terminus. We subjected the
AES_7139 protein sequence to BLAST search and
showed that there is 100% amino acid sequence identity
with a hypothetical protein (PA2G_05851) from P. aeru-
ginosa PA2192 (Blastp score 311, query coverage 100%, e-
value 2e-83), an isolate from a chronically infected CF
patient in Boston. Other matches displayed similarity to
ricin B-type lectins, suggesting the protein might be
involved in carbohydrate binding. Importantly, however,
no other P. aeruginosa genomes within the Swiss-Prot
database contained AES_7139 homologs.
Comparative gel-free proteomics of P. aeruginosa PAO1,
PA14 and AES-1R using iTRAQ labelling and 2-DLC/MS-MS
Proteins from stationary phase cultures of P. aeruginosa
AES-1R, PAO1 and PA14 were proteolytically digested,
labeled using iTRAQ and analysed by 2-DLC-MS/MS.
Multiple experiments were performed such that each
Figure 1 Two-dimensional gel electrophoresis of proteins from P. aeruginosa AES-1R (A), PAO1 (B), and PA14 (C). Spot numbers refer to
protein identifications as shown in Additional file 2. Boxes indicate positions of multiple spots with the same identification.
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strain was analysed in duplicate. Proteins with a ratio >
1.5 or < 0.67 (p-value < 0.05), and > 1.3 or < 0.77
(p-value < 0.01) were considered to be statistically differ-
entially abundant. We identified a total of 1788 unique
P. aeruginosa proteins, of which 1355 could be accu-
rately quantified across the strains using iTRAQ. 162
proteins displayed significant differential abundance
between the P. aeruginosa strains (Additional file 3). Of
these, 60 were regulated identically between AES-1R
compared to both PAO1 and PA14, 55 were only found
in AES-1R versus PAO1, 39 were only found in AES-1R
versus PA14 and 8 were differently abundant in AES-1R
compared to both PAO1 and PA14, but in the opposite
direction (e.g. more abundant in AES-1R compared to
PAO1, but less abundant in AES-1R compared to
PA14).
Functional analysis of the differently abundant proteins
showed they could be clustered into 6 major groups: i)
virulence determinants (including proteins involved in
iron acquisition, phenazine biosynthesis and secreted fac-
tors); ii) membrane-associated proteins (including proteins
involved in transport, antibiotic efflux, lipopolysaccharide
(LPS) biosynthesis and outer membrane proteins [OMP]);
iii) transcriptional and regulatory proteins; iv) proteins
involved in translation; v) metabolic proteins; and vi) pro-
teins of no known function. Of the 123 proteins found to
be significantly altered in abundance between AES-1R and
PAO1, 83 were present at elevated abundance in the AES-
1R strain (40 present at reduced abundance); while of the
105 proteins significantly altered in abundance between
AES-1R and PA14, 73 were present at increased abun-
dance in AES-1R (32 present at reduced abundance).
Within the functional clusters, proteins could also be clas-
sified by their relative abundance when compared between
strains. For example, proteins involved in translation (pre-
dominantly ribosomal proteins) were overwhelmingly
more abundant in AES-1R than either PA14 or PAO1
(Additional file 3).
We observed changes in abundance of several proteins
thought to be involved in P. aeruginosa virulence. AES-1R
displayed increased levels of chitinase ChiC, chitin-binding
protein CbpD (PA0852), putative hemolysin (PA0122),
hydrogen cyanide synthase HcnB (PA2194), while reduced
abundance was detected for several other secreted proteins
(e.g. Azurin, LasB elastase). It is important to note how-
ever, that these studies examined only intracellular pro-
teins and do not reflect the amount of protein released
into the extracellular environment during stationary phase
growth. The LasB data do however, correlate with the phe-
notypic results observed from the elastase assays, where
AES-1R produced more extracellular elastase function
than PAO1, but less than PA14. Abundance differences
could be detected for 4 proteins involved in the synthesis
(PchEFG) or retrieval (FptA receptor) of the siderophore
Figure 2 Predicted protein sequence of a P. aeruginosa AES-1R hypothetical protein ((A); AES_7139; spot 43a-e) characterized by
MALDI-MS and LC-MS/MS (B). Peptide Mass, peptides observed by either LC-MS/MS (charge states > +1) or by peptide mapping (charge state
+1); Sequence, peptide sequence defined by assignment of y- and b-ions and confirmed by manual interpretation of the MS/MS spectra
(920.4535 (+1); matched by mass alone); Note, modifications to sequence identified by MS. Peptides identified by MS are underlined in the
protein sequence. Note the non-tryptic N-terminal peptide (958.5200 (+3) m/z), suggesting the methionine at position 7 is the true N-terminus.
Cysteine residue potentially involved in disulfide bond/homodimer formation is marked with (*).
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pyochelin. Interestingly, these were present at increased
abundance in AES-1R when compared to PAO1, but
reduced in AES-1R when compared to PA14. AES-1R also
displayed reduced levels of other proteins involved in iron
maintenance, including BfrA and BfrB bacterioferritin,
although increased levels of a putative bacterioferritin
(PA4880) were observed.
AES-1R displayed several changes associated with mem-
brane transport and OMPs. Proteins with elevated abun-
dance were associated with amino acid binding and small
molecule transport (e.g. AotJ [PA0888], BraC [PA1074]
and PhuT [PA4708]), as well as several lipoproteins,
including OsmE (PA4876). AES-1R displayed highly ele-
vated abundance of the type IV pilin structural subunit
PilA (> 4-fold increase in abundance versus both PAO1
and PA14), as well as putative OMPs PA1689 and OmpA
(PA3692), and the multi-drug efflux system protein MexX.
The abundance difference for PilA in AES-1R may how-
ever be due to significant sequence differences between
the 3 strains for this protein leading to an artificially
inflated ratio (4.08 and 4.52 for PAO1 and PA14, respec-
tively). Interestingly, a single AES-1R-specific protein
(referred to here as AES_7145) with sequence similarity to
an O-antigen/alginate biosynthesis protein UDP-N-acetyl-
D-mannosaminuronate dehydrogenase, was also identified
at very high levels in AES-1R. AES_7145 does not have a
closely related homolog in either PAO1 or PA14 (< 50%
sequence similarity to nearest match; data not shown)
resulting in high iTRAQ reporter ratios (i.e. 3.835 versus
PAO1 and 9.563 versus PA14). A sequence homolog was
identified in the Liverpool CF epidemic strain LESB58
(PLES_19091 or WbpO; Blastp score 466, 97% sequence
identity, e-value 9e-130). We also identified a second O-
antigen biosynthesis protein, putative UDP-N-acetylgluco-
samine 2-epimerase (OrfK; PA14_23370), which appears
to be unique to PA14. The presence of these proteins may
reflect a difference in the LPS expressed in these strains.
Other LPS proteins (e.g. lipid A 3-O-deacylase [PagL;
PA4661]; 2-dehydro-3-deoxyphosphooctonate aldolase
[KdsA; PA3636] and PslE [PA2235; unknown function in
exopolysaccharide biosynthesis]) were also present in
AES-1R at statistically significant altered abundance levels.
PagL and KdsA however, were present at reduced abun-
dance in AES-1R, along with several OMPs (OprD, OprG,
OpmD, OprB2, OprQ and TolQ).
A number of proteins related to DNA replication, cell
division and transcriptional regulation were observed to
be differentially abundant between AES-1R and PAO1/
PA14 (Additional file 3). The majority of these were pre-
sent at increased abundance in AES-1R, including DNA-
directed RNA polymerase alpha, beta and beta*
(RpoABC; PA4238, PA4269 and PA4270), FtsH cell divi-
sion protein (PA4751), Rho transcription termination
factor (PA5239), histone-like protein HU (PA3940) and
DNA gyrase subunit A (GyrA; PA3168). Inspection of
the AES-1R GyrA protein sequence revealed an amino
acid substitution of Thr83Ile (ACC- > ATC) (data not
shown), which is a reported mutation in a number of CF
clinical isolates showing quinolone resistance [34]. This
mutation is also shared with the Liverpool epidemic
strain LESB58 GyrA (PLES_19001). Interestingly, AES-1R
showed increased abundance of the ferric uptake regula-
tor (Fur; PA4764) in comparison to both PAO1 and
PA14, although the degree of this increase was greater in
comparison to PA14. Fur is the master regulator (repres-
sor) of iron acquisition-related genes [35], and increased
Fur levels are consistent with decreased abundances
observed for several iron acquisition proteins (PchEFG,
FptA, PA5217) when compared between AES-1R and
PA14. Conversely however, we observed increased abun-
dances of several of these proteins in AES-1R compared
to PAO1, despite elevated Fur. Seven proteins were less
abundant in AES-1R than in PAO1 or PA14, including 2
transcriptional regulators (MvaT [PA4315] and PA2667),
and the RecG DNA helicase.
All differentially abundant proteins functionally clus-
tered into the translation category were present at
increased abundance in AES-1R. These were predomi-
nantly ribosomal proteins (13 proteins), although both
elongation factors G and Ts were also present. Chapero-
nins GroEL, DnaK and HtpX were also present at elevated
abundance in AES-1R. Forty-two proteins functionally
classified as ‘metabolic proteins’ were present at altered
abundance in AES-1R compared to PAO1 and PA14. Sub-
clusters within this broad functional category were also
readily identified. Ten proteins involved in fatty acid bio-
synthesis and metabolism were altered in abundance
including 7 that were more abundant in AES-1R (FabB
[PA1609], FabG [PA2967], acetyl-CoA carboxylase alpha
[AccA; PA3639] and beta [AccD; PA3112], acyl carrier
protein AcpP [PA2966], acyl-CoA thiolase [AspC;
PA4785] and (R)-specific enoyl-CoA hydratase [PhaJ4;
PA4015]). Twelve of the remaining proteins were func-
tionally classified as playing a role in amino acid biosynth-
esis or degradation. Data for the three enzymes (ArcABC)
of the arginine deiminase pathway showed all were present
at elevated abundance in AES-1R compared to PA14, but
were at lower levels in AES-1R than in PAO1. These
results are in agreement with our 2-DE-based observations
for AES-1R compared to PA14, where all three of ArcABC
were present in higher abundance (or could only be
observed) on gels derived from AES-1R. For AES-1R com-
pared to PAO1 however, the data conflict to some degree
since no difference between these two strains could be
observed for arginine deiminase (ArcA), while carbamate
kinase (ArcC) appeared to be significantly higher in AES-
1R than PAO1. These results most likely reflect the ability
to distinguish different mass and pI variants when using
Hare et al. BMC Microbiology 2012, 12:16
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2-DE-based approaches, whereas the iTRAQ peptide-
based quantification technique reflects overall protein
levels irrespective of chemical or physical protein post-
translational modifications. This is further highlighted by
our ability to identify 4 different forms of the ArcB
ornithine carbamoyltransferase on 2-DE gels (Additional
file 2).
The final functional group consisted of previously desig-
nated ‘hypothetical’ proteins, or proteins of no known
function. Of these, one was encoded by a gene found only
in AES_1R, while a second was only encoded by PA14.
The AES-1R-specific hypothetical protein sequence
(labelled here as AES_7165) was subjected to a BLAST
sequence search and contained a region of sequence simi-
larity to a type II restriction endonuclease (Cfr42I) from
Citrobacter freudii (score 309, query coverage 100%,
e-value 1e-82; data not shown). The other strain specific
protein we identified was unique to PA14 (labelled
PA14_53590). We were unable to find any sequence simi-
larity between this hypothetical protein and any sequenced
Pseudomonas or other bacterial gene/protein sequence.
Comparison of gel-based and gel-free approaches for
profiling P. aeruginosa strain differences
The overwhelming advantage of the gel-free approach was
the ability to analyse the proteome at a much greater
depth than a 2-DE gel-based approach. Gel-free analysis
allowed the identification of 162 proteins that were altered
in abundance between strains, while 2-DE enabled the
identification of only 43 such proteins. Analysis of these 2
data sets showed that 22 proteins were identified as
‘altered’ by both 2-DE and iTRAQ 2-DLC/MS-MS (Addi-
tional file 2). The remaining 21 proteins identified by 2-
DE were all characterized by gel-free means, and the
majority showed the same n-fold change, but could not be
included since they did not reach the required rigorous
statistical cut-off for significance. The data do however;
show a typical distribution for comparison of 2-DE and 2-
DLC/MS-MS, where the majority of both identifications
and quantified changes can be observed using gel-free
means, yet some unique data (typically relating to protein
degradation/fragmentation; e.g. OmpA or other modifica-
tions) are obtained using gel-based approaches. For the
overlapping 22 proteins, we compared the data derived
from both 2-DE densitometry and iTRAQ gel-free techni-
ques (Additional file 4; 44 comparisons–AES-1R com-
pared to PAO1 and PA14). The increases and decreases in
abundance were generally consistent across techniques for
most proteins (22/44 comparisons and a further 11/44
where the iTRAQ ratios were not statistically significant
for inclusion). 9/44 were detected as changing by iTRAQ
2-DLC/MS-MS but were apparently not changing on 2-
DE gels, while only 2/44 comparisons showed opposite
changes. These last two groups contained many proteins
that appear as multiple protein ‘spots’ on 2-DE gels (e.g.
ArcB) and thus it is difficult to gauge the overall abun-
dance of those proteins by the gel-based approach.
Discussion
This study compared proteome profiles of 3 P. aeruginosa
strains to identify candidate proteins that may be specific
to the acute, transmissible CF strain AES-1R. Proteins
identified in the AES-1R isolate may reflect adaptations
specific to the environmental niche of this organism and
that could provide a colonization advantage in the CF
lung. A number of virulence determinants differed in
abundance between strains, including secreted factors,
siderophore and pigment producing enzymes, and oxida-
tive stress response proteins. P. aeruginosa is known to
produce a number of secreted virulence factors including
toxins, proteases and binding proteins, many of which are
under QS regulation [36,37]. AES-1R protein profiles dis-
played elevated abundances of chitinase ChiC, chitin-bind-
ing protein CbpD, and putative hemolysin (PA0122), while
the major secreted protease elastase LasB was increased in
virulent PA14. Microarray studies have shown increased
expression of hcnB and cbpD in mucoid P. aeruginosa
compared to non-mucoid [38]. Since AES-1R is non-
mucoid, it is possible that these proteins are more abun-
dant in CF isolates irrespective of mucoidy when com-
pared to non-CF strains. Comparisons of a chronic, rather
than acute, CF isolate with PAO1 also showed increased
cbpD gene expression [25]. Putative hemolysin (PA0122)
is highly expressed in non-mucoid CF clinical isolates and
binds oxidised low-density lipoprotein from human serum
present in the CF lung [39,40]. Increased chitinase produc-
tion may provide AES-1R with an enhanced ability to
degrade lung connective tissues [41]. We also observed
elevated abundance in AES-1R of PasP (PA0423), a small
protease that cleaves collagens and a virulence determi-
nant in P. aeruginosa-associated corneal infections [42].
PasP has been described as an immunogen in 4 CF patient
sera [43]. Importantly, it must be noted that our data
reflect intracellular levels of these predominantly secreted
proteins, suggesting either altered expression or impaired
secretion. We were able to detect higher elastase and total
protease activities for AES-1R compared to PAO1, while
total hemolysin activity was approximately the same. Simi-
lar to the proteomics data, we observed reduced elastase
activity for AES-1R compared to PA14.
P. aeruginosa produces compounds such as pyocyanin
(induction of oxidative damage and pro-inflammatory
effect reviewed by [44]), hydrogen cyanide (decoupling
host cell respiration), and siderophores for the scavenging
of iron. Pyocyanin exerts multiple detrimental effects on
the host, primarily through its ability to produce reactive
oxygen species, and is capable of repressing transcription
of host oxidative stress defense proteins [45], interfering
Hare et al. BMC Microbiology 2012, 12:16
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with metabolism [46], inhibiting beating of cilia [47],
proinflammatory action [48], neutrophil apoptosis [49]
and increased levels correlate with CF pulmonary exacer-
bations [50]. P. aeruginosa possesses two operons
(phzA1B1C1D1E1F1G1 and phzA2B2C2D2E2F2G2) for
the synthesis of phenazine-carboxylic acid (PCA), which is
then further processed by PhzM to 1-hydroxyphenazine
(1-HP) and finally, PhzS to pyocyanin. These intermediates
also exhibit cytotoxic effects on the host [47,51,52]. We
observed elevated levels of PhzS in AES-1R compared to
PAO1 (gel-free approach) and PA14 (2-DE gel-based ana-
lysis), yet a decrease in comparative PhzB2 levels.
Increased PhzS may reflect elevated 1-HP to pyocyanin,
which is supported by several studies showing pyocyanin
production is enhanced in CF strains [53,54] and reflected
in AES-1R phenotypic data compared to PAO1 (Table 1).
Decreased PhzB2 abundance may reflect differential
induction of the 2 Phz operons across strains [47,51,52,55].
Iron acquisition via siderophore production is critical for
successful colonization of the CF lung and for providing
P. aeruginosa with a distinct competitive advantage over
other pathogens. The host generally limits free iron by
sequestration via transferrin, ferritin and lactoferrin. The
CF lung may contain higher iron availability (CF, 13-32
μmol.L-1 c.f. normal 0-13.2 μmol.L-1 [56]), most likely due
to tissue damage resulting from an exaggerated inflamma-
tory response. P. aeruginosa produces the pyochelin and
pyoverdine siderophores to acquire iron from the environ-
ment and the later is thought to be a major contributor in
the CF lung [57]. We observed increases in abundance of
pyochelin synthetases (PchEF) in AES-1R compared to
PAO1. Transcriptomic studies have also shown increased
expression of pchEF in a chronic CF isolate [25]. In con-
trast, PA14 produced even greater levels of PchEF, as well
as pyochelin synthetase PchG and the Fe(III)-pyochelin
outer membrane receptor FptA. This confirms that iron
acquisition is important in general virulence as well as in
the specific CF lung micro-environment. Other proteins
involved in iron uptake and storage were differentially
abundant between the strains studied. The iron storage
bacterioferritins BfrA and BfrB were decreased in abun-
dance in AES-1R, however a putative bacterioferritin
PA4880 was markedly increased in abundance suggesting
it may be the preferred storage protein in this isolate.
These data correlated with previous transcript analyses–
increased expression of pa4880 was observed in a chronic
CF isolate compared to PAO1 [25], while decreased bfrB
was observed under iron starvation suggesting AES-1R is
adapted to an iron-limited environment [58].
CF-associated AES-1R was the only strain with detect-
able flagellin in the protein extracts analysed by 2-DE.
AES-1R FliC has significant protein sequence differences
compared with PAO1 and PA14, and has greater
sequence similarity with the type A flagellin of strain
PAK (Additional file 5). Increased flagellin in AES-1R is
consistent with our phenotypic data for swimming moti-
lity and with previous work showing AES-1 isolates dis-
played greater motility than non-clonal CF isolates [59].
Several differences in the OMP profile of AES-1R were
observed. The loss of OprD in AES-1R is characteristic of
carbapenem antibiotic resistance [60]. Decreased OprG
expression was originally associated with increased fluor-
oquinolone resistance [61], however a recent study
showed no significant difference in the antibiotic suscept-
ibility profile of an oprG-deficient strain [62]. ΔoprG
P. aeruginosa do show a 3-fold decrease in cytotoxicity
toward the human bronchial epithelial cell line HBE,
however transcriptomics revealed a rapid down-regula-
tion of oprG in wild-type P. aeruginosa upon interaction
with these cells [62]. MexX, a component of the MexXY-
OprM multidrug efflux transporter, was markedly
increased in abundance in AES-1R and is known to con-
fer resistance to a number of antibiotics including ery-
thromycin, fluoroquinolones, aminoglycosides and the
ß-lactams, cefepime and ceftobiprole [63-66], correlating
well with the antibiotic resistance associated with CF
infections. Quinolones are the antibiotic of choice for
treatment of P. aeruginosa CF lung infections and resis-
tance to this class of drug can result from mutations
within DNA gyrase GyrA (PA3168), which is essential for
DNA replication. The AES-1R gyrA gene sequence
revealed an amino acid substitution (Thr83Ile) previously
reported to result in quinolone resistance [34] and
observed in the Liverpool epidemic strain LESB58.
Increased abundance of PA5178 (putative LysM domain
protein), a protein containing a domain with predicted
bacterial wall degradation properties may suggest a
potential advantage against competing pathogens. P. aer-
uginosa is predicted to contain approximately 185 genes
encoding lipoproteins [67]. A number of lipoproteins
were observed at increased abundance in AES-1R. Induc-
tion of lipoprotein genes has been associated with an
excessive proinflammatory response in lung epithelial
cells via Toll-like receptor 2 [68]. OprI (PA2853) is an
immunogenic lipoprotein that has been proposed as part
of a multivalent vaccine [69]. We observed reduced OprI
abundance in AES-1R, which may influence the efficacy
of an OprI-based vaccine.
LPS is a major virulence factor that is involved in
initiating the pro-inflammatory response in the host.
P. aeruginosa strains produce different LPS types, which
are currently classified into 20 serotypes. Strain-specific
enzymes involved in O-antigen synthesis were identified
in AES-1R (UDP-N-acetyl-D-mannosaminuronate dehy-
drogenase (AES_7145)) and PA14 (putative UDP-N-
acetylglucosamine 2-epimerase OrfK (PA14_23370)) and
these may reflect serotype differences. LPS has also been
implicated in evasion of the host immune response and
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antibiotic resistance in CF lung infection [70,71]. The
LPS modification enzyme lipid A 3-O-deacylase PagL
(PA4661) catalyses the production of a penta-acylated
lipid A [72]. Reduced abundance of PagL in AES-1R
(compared with PA14) is consistent with previous find-
ings showing a third of P. aeruginosa isolates from CF
patients with severe lung disease produced hexa- or
hepta-acylated lipid A, due to a decrease in 3-O-deacy-
lase activity [71]. A consistent finding in AES-1R was
increased abundance of enzymes involved in fatty acid
biosynthesis. Further weight is given to this evidence
from transcriptomic results showing increased expres-
sion levels of fatty acid biosynthesis enzymes in a
chronic CF isolate compared to PAO1 [25]. This collec-
tion of pathways supplies an essential building block
used in a number of cell processes, particularly mem-
brane synthesis and provides the acyl groups necessary
for the synthesis of acyl-homoserine lactones (AHLs)
[73], the autoinducer signal molecules necessary for QS.
Our studies allowed the identification of previously
hypothetical proteins, particularly those unique to AES-
1R. A protein of unknown function (AES_7139) was the
most abundant observed on the 2-DE profiles of AES-1R.
AES_7139 is found in a large region of the AES-1R gen-
ome (AES_6966 to _7152) containing nearly entirely AES-
1R-specific coding sequences [30]. This protein sequence
could only be found by BLAST search in a second CF-
associated P. aeruginosa isolate (hypothetical protein
PA2G_05851 from P. aeruginosa PA2192; [19]), and con-
tains a ricin-type lectin conserved domain that is asso-
ciated with carbohydrate binding. Analysis of mucin
glycosylation in the sputum of CF patients has shown
altered glycan patterns, consisting of increased sialylation
and reduced sulfation and fucosylation [74,75]. Since
mucin glycan structures may be altered, specific proteins
such as AES_7139/PA2G_05851 could be necessary for
binding lung epithelium. Certainly the overall abundance
detected here suggests a central role for this protein in the
environmental survival of AES-1R and a potential role in
early infection. A further two AES-1R-specific hypothetical
proteins (AES_7104 and AES_7165) were also identified.
Approximately a third of the theoretical P. aeruginosa
proteome (1788 proteins) was identified by gel-free 2-
DLC/MS-MS, with 75% of these providing sufficient data
for accurate quantitation. The 2-DE approach however
does allow for the relative abundance of individual pro-
teins to be compared within a sample (for example,
AES_7139 as the most abundant ‘spot’ in comparison to
all other protein spots). 2-DE also provides additional
information regarding protein variants, processing or post-
translational modification, as well as facilitating the identi-
fication of proteins with sequence differences compared to
genomically characterized relatives or highlighting mis-
annotations within a gene sequence (e.g. flagellin (FliC/
FlaA) and type IV pilin types (PilA)). Transcriptomic ana-
lyses are able to quantitate gene expression accurately up
to 4.7 orders of magnitude [76], however proteomic strate-
gies such as iTRAQ only achieve measurement of around
2 orders of magnitude. Technical limitations of the
iTRAQ method may lead to an underestimation of the
magnitude of change [77], while many proteins are below
the limit of detection by 2-DE. Clear examples of iTRAQ
ratio underestimation are seen in proteins that are unique
to a particular strain, such as AES_7165 (unique to AES-
1R), which despite being absent in PAO1 and PA14 only
achieved measured ratios of 4.15 and 4.90, respectively.
Conclusions
A complementary proteomic approach combining gel-
based (2-DE) and gel-free (2-DLC-MS/MS with iTRAQ
tags) techniques was employed to quantitatively compare
the proteomes of P. aeruginosa strains PAO1, PA14 and
AES-1R (an acute, transmissible CF isolate). Proteins asso-
ciated with AES-1R belonged to a variety of functional
groups including virulence factors, antibiotic resistance,
LPS and fatty acid biosynthesis, and several hypothetical
proteins. Proteins involved in the acquisition of iron were
elevated in AES-1R compared to PAO1, while being
decreased compared to PA14. These results confirm that
CF-associated P. aeruginosa strains express a unique pro-
tein profile indicative of phenotypic adaptations to their
environment and that provide traits conferring an advan-
tage in colonization of the CF lung micro-environment.
Identification of the proteins used by transmissible strains
will aid in the elucidation of novel intervention strategies
to reduce the burden of P. aeruginosa infection in CF
patients.
Additional material
Additional file 1: Growth curves for P. aeruginosa AES-1R, PAO1 and
PA14 grown to stationary phase in LB medium. Dotted line and *,
harvest time for PAO1 and PA14; #, for AES-1R.
Additional file 2: Table containing identification of differentially
abundant proteins in P. aeruginosa AES-1R compared to PAO1 and
PA14 using 2-DE.
Additional file 3: Table containing identification of differentially
abundant proteins in P. aeruginosa AES-1R compared to PAO1 and
PA14 using iTRAQ.
Additional file 4: Figure showing overlap of identified and
quantified proteins by 2-DE and 2-DLC/MS with iTRAQ. Table
showing relative abundance changes for 22 proteins quantified by both
2-DE and iTRAQ.
Additional file 5: Protein sequence alignment of Flagellin (FliC/FlaA)
of P. aeruginosa strains used in this study (AES_1954, PA1092, and
PA14_50290) and including an additional sequence from strain PAK
with a known type A flagellin. The flagellin sequence of strain AES-1R
has higher sequence similarity with the shorter A type flagellin of strain
PAK (95%), while the type B flagellins of strains PA14 and PAO1 are
almost identical with only a single amino acid difference.
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